Target Binding of Black Phosphorus Nanomaterial to Polo-Like Kinase 1 for Cancer Chemotherapy: A Mutual Selection of Nanomaterial and Protein

Abstract

The intrinsic properties of black phosphorus (BP) nanomaterials (NMs) enable them for targeted binding to polo-like kinase 1 (PLK1), thus inhibiting its kinase activity. However, the mechanism and targeted binding sites underlying this interaction remain unclear. To elucidate the critical properties of PLK1 that facilitate its interaction with BPNMs, the binding ability of BPNMs was compared across PLK family proteins. Although BPNMs exhibited a weak binding affinity for PLK3, PLK1 demonstrated the most favorable physicochemical properties for its binding. Factors as surface charge, hydrophobicity, secondary and three-dimensional structures significantly affected the interaction of PLK family proteins to BPNMs. The binding affinity was primarily determined by amino acid residues at the binding interface, where arginine and proline played critical roles in mediating the interaction of BPNMs-PLK1. BPNMs inhibited PLK1 activation by binding to key residues of the kinase domain, including S49, Y203, D204, E206, and R207. In conclusion, this study elucidates the molecular basis of the specific interaction between BPNMs and PLK1, highlighting the pivotal role of the amino acid residues in NM-protein binding. This work demonstrates that NM-protein interactions are a mutual selection and driven by the physicochemical properties of both proteins and NMs.

Keywords

black phosphorus nanomaterials / PLK family / PLK1 inhibitor / protein structure / targeted interaction of nanomaterial with protein

References

[1] M. A. Younis, H. M. Tawfeek, A. A. H. Abdellatif, J. A. Abdel-Aleem, and H. Harashima, “Clinical Translation of Nanomedicines: Challenges, Opportunities, and Keys,” Advanced Drug Delivery Reviews181 (2022): 114083.

[2] C. Zhang, L. Yan, X. Wang, et al., “Progress, Challenges, and Future of Nanomedicine,” Nano Today35 (2020): 101008.

[3] P. Breznica, R. Koliqi, and A. Daka, “A Review of the Current Understanding of Nanoparticles Protein Corona Composition,” Medicine and Pharmacy Reports93 (2020): 342-350.

[4] T. Cedervall, I. Lynch, S. Lindman, et al., “Understanding the Nanoparticle–Protein Corona Using Methods to Quantify Exchange Rates and Affinities of Proteins for Nanoparticles,” PNAS104 (2007): 2050-2055.

[5] a) M. Hadjidemetriou and K. Kostarelos, “Evolution of the Nanoparticle Corona,” Nature Nanotechnology12 (2017): 288-290. b) R. Cai, J. Ren, M. Guo, et al., “Dynamic Intracellular Exchange of Nanomaterials′ Protein Corona Perturbs Proteostasis and Remodels Cell Metabolism,” PNAS119 (2022): e2200363119.

[6] M. Lundqvist, J. Stigler, G. Elia, I. Lynch, T. Cedervall, and K. A. Dawson, “Nanoparticle Size and Surface Properties Determine the Protein Corona With Possible Implications for Biological Impacts,” PNAS105 (2008): 14265-14270.

[7] C. D. Walkey, J. B. Olsen, F. Song, et al., “Protein Corona Fingerprinting Predicts the Cellular Interaction of Gold and Silver Nanoparticles,” ACS Nano8 (2014): 2439-2455.

[8] a) S. Dhar, V. Sood, G. Lohiya, H. Devenderan, and D. S. Katti, “Role of Physicochemical Properties of Protein in Modulating the Nanoparticle-Bio Interface,” Journal of Biomedical Nanotechnology16 (2018): 1276-1295. b) A. N. Abraham, T. K. Sharma, V. Bansal, and R. Shukla, “Phytochemicals as Dynamic Surface Ligands To Control Nanoparticle–Protein Interactions,” ACS Omega3 (2018): 2220-2229. c) D. Baimanov, R. Cai, and C. Chen, “Understanding the Chemical Nature of Nanoparticle–Protein Interactions,” Bioconjugate Chemistry30 (2019): 1923-1937.

[9] a) W. Zhang, Q. Zhang, F. Wang, et al., “Comparison of Interactions Between Human Serum Albumin and Silver Nanoparticles of Different Sizes Using Spectroscopic Methods,” Luminescence30 (2015): 397-404. b) M. Suvarna, S. Dyawanapelly, B. Kansara, P. Dandekar, and R. Jain, “Understanding the Stability of Nanoparticle–Protein Interactions: Effect of Particle Size on Adsorption, Conformation and Thermodynamic Properties of Serum Albumin Proteins,” ACS Applied Nano Materials1 (2018): 5524-5535.

[10] L. Marichal, G. Klein, J. Armengaud, et al., “Protein Corona Composition of Silica Nanoparticles in Complex Media: Nanoparticle Size Does Not Matter,” Nanomaterials (Basel)10 (2020): 240.

[11] a) S. R. Saptarshi, A. Duschl, and A. L. Lopata, “Interaction of Nanoparticles With Proteins: Relation to Bio-Reactivity of the Nanoparticle,” Journal of Nanbiotechnology11 (2013): 26. b) J. Yang, L. Wang, L. Huang, et al., “Receptor-Targeting Nanomaterials Alleviate Binge Drinking-Induced Neurodegeneration as Artificial Neurotrophins,” Exploration (Beijing)1 (2021): 61-74.

[12] D. Docter, D. Westmeier, M. Markiewicz, S. Stolte, S. K. Knauer, and R. H. Stauber, “The Nanoparticle Biomolecule Corona: Lessons Learned—Challenge Accepted?,” Chemical Society Reviews44 (2015): 6094-6121.

[13] G. Zhang, Y. Cong, F. L. Liu, et al., “A Nanomaterial Targeting the Spike Protein Captures SARS-CoV-2 Variants and Promotes Viral Elimination,” Nature Nanotechnology17 (2022): 993-1003.

[14] G. Zhang, X. Wang, G. Wang, et al., “Nanoparticles Insert a Three Dimensional Cavity Structure of Proteins for Function Inhibition: The Case of CeO₂ and SARS-CoV-2,” Nano Today55 (2024): 102183.

[15] B. Wu, G. Zhang, J. Ji, et al., “ZIF-67-Derived Antivirus Cobalt Hydroxide LDH Nanosheets Produced through High-Concentration Cobalt Ion-Assisted Hydration,” Advanced Functional Materials34 (2023): 2312941.

[16] S. Zitouni, C. Nabais, S. C. Jana, A. Guerrero, and M. Bettencourt-Dias, “Polo-Like Kinases: Structural Variations Lead to Multiple Functions,” Nature Reviews Molecular Cell Biology15 (2014): 433-452.

[17] a) S. Y. Lee, C. Jang, and K. A. Lee, “Polo-Like Kinases (Plks), a Key Regulator of Cell Cycle and New Potential Target for Cancer Therapy,” Development & Reproduction18 (2014): 65-71. b) Z. Liu, Q. Sun, and X. Wang, “PLK1, A Potential Target for Cancer Therapy,” Translational Oncology10 (2017): 22-32. c) Z. Zhang, E. Liu, D. Zhang, et al., “The Expression and Clinical Significance of PLK1/p-PLK1 Protein in NK/T Cell Lymphoma,” Diagnostic Pathology18 (2023): 129. d) S. Shin, H. Jang, R. Xu, J. Won, and H. Yim, “Active PLK1-Driven Metastasis is Amplified by TGF-β Signaling That Forms a Positive Feedback Loop in Non-Small Cell Lung Cancer,” Oncogene39 (2020): 767-785. e) L. Gheghiani, L. Wang, Y. Zhang, et al., “PLK1 Induces Chromosomal Instability and Overrides Cell-Cycle Checkpoints to Drive Tumorigenesis,” Cancer Research81 (2021): 1293-1307. f) R. E. Gutteridge, M. A. Ndiaye, X. Liu, and N. Ahmad, “Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics,” Molecular Cancer Therapeutics15 (2016): 1427-1435.

[18] S. Shin, S. Woo, and H. Yim, “Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-Binding Domain or Polo-Box Domain,” Journal of Cellular Physiology230 (2015): 3057-3067.

[19] a) Y. Jung, P. Kraikivski, S. Shafiekhani, S. S. Terhune, and R. K. Dash, “Crosstalk Between Plk1, p53, Cell Cycle, and G2/M DNA Damage Checkpoint Regulation in Cancer: Computational Modeling and Analysis,” npj Systems Biology and Applications7 (2021): 46. b) I. Elsayed and X. S. Wang, “PLK1 Inhibition in Cancer Therapy: Potentials and Challenges,” Future Medicinal Chemistry11 (2019): 1383-1386.

[20] K. S. Lee, T. R. Burke , J. E. Park, J. K. Bang, and E. Lee, “Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy,” Trends in Pharmacological Sciences36 (2015): 858-877.

[21] J. M. Stafford, M. D. Wyatt, and C. McInnes, “Inhibitors of the PLK1 Polo-Box Domain: Drug Design Strategies and Therapeutic Opportunities in Cancer,” Expert Opinion Drug Discovery18 (2023): 65-81.

[22] W. Zhou, T. Pan, H. Cui, Z. Zhao, P. K. Chu, and X. F. Yu, “Black Phosphorus: Bioactive Nanomaterials With Inherent and Selective Chemotherapeutic Effects,” Angewandte Chemie58 (2019): 769-774.

[23] X. Shao, Z. Ding, W. Zhou, et al., “Intrinsic Bioactivity of Black Phosphorus Nanomaterials on Mitotic Centrosome Destabilization Through Suppression of PLK1 Kinase,” Nature Nanotechnology16 (2021): 1150-1160.

[24] a) L. Peng, N. Abbasi, Y. Xiao, and Z. Xie, “Black Phosphorus: Degradation Mechanism, Passivation Method, and Application for In Situ Tissue Regeneration,” Advanced Materials Interfaces7, no. 23 (2020): 2001538. b) Y. Hou, Y. Fei, Z. Liu, Y. Liu, M. Li, and Z. Luo, “Black Phosphorous Nanomaterials as a New Paradigm for Postoperative Tumor Treatment Regimens,” Journal of Nanbiotechnology20 (2022): 366.

[25] G. Qu, T. Xia, W. Zhou, et al., “Property-Activity Relationship of Black Phosphorus at the Nano-Bio Interface: From Molecules to Organisms,” Chemical Reviews120 (2020): 2288-2346.

[26] a) B. Yang, H. Lin, C. Dai, Y. Chen, and J. Shi, “Stepwise Extraction″ Strategy-Based Injectable Bioresponsive Composite Implant for Cancer Theranostics,” Biomaterials166 (2018): 38-51. b) B. Yang, J. Yin, Y. Chen, et al., “2D-Black-Phosphorus-Reinforced 3D-Printed Scaffolds: A Stepwise Countermeasure for Osteosarcoma,” Advanced Materials30 (2018): 10705611. c) B. Yang, L. Ding, Y. Chen, and J. Shi, “Augmenting Tumor-Starvation Therapy by Cancer Cell Autophagy Inhibition,” Advanced Science7 (2020): 1902847. d) B. Yang, Y. Chen, and J. Shi, “Material Chemistry of Two-Dimensional Inorganic Nanosheets in Cancer Theranostics,” Chemistry4: 1284-1313.

[27] R. H. Fang, W. Gao, and L. Zhang, “Targeting Drugs to Tumours Using Cell Membrane-Coated Nanoparticles,” Nature Reviews Clinical Oncology20 (2023): 33-48.

[28] B. D. Roorda, A. ter Elst, W. A. Kamps, and E. S. de Bont, “Bone Marrow-Derived Cells and Tumor Growth: Contribution of Bone Marrow-Derived Cells to Tumor Micro-Environments With Special Focus on Mesenchymal Stem Cells,” Critical Reviews in Oncology/Hematology69 (2009): 187-198.

[29] a) Z. Sun, H. Xie, S. Tang, et al., “Ultrasmall Black Phosphorus Quantum Dots: Synthesis and Use as Photothermal Agents,” Angewandte Chemie (International Edition in English)54 (2015): 11526-11530. b) J. Shao, C. Ruan, H. Xie, et al., “Black-Phosphorus-Incorporated Hydrogel as a Sprayable and Biodegradable Photothermal Platform for Postsurgical Treatment of Cancer,” Advanced Science5 (2018): 1700848.

[30] C. F. Macrae, P. R. Edgington, P. McCabe, et al., “Mercury: Visualization and Analysis of Crystal Structures,” Journal of Applied Crystallography39 (2006): 453-457.

[31] E. F. Pettersen, T. D. Goddard, C. C. Huang, et al., “UCSF Chimera—A Visualization System for Exploratory Research and Analysis,” Journal of Computational Chemistry25 (2004): 1605-1612.

[32] Y. Gao, C. Zhang, X. Wang, and T. Zhu, “A Test of AMBER Force Fields in Predicting the Secondary Structure of α-helical and β-hairpin Peptides,” Chemical Physics Letters679 (2017): 112-118.

[33] R. Anandakrishnan, B. Aguilar, and A. V. Onufriev, “H++ 3.0: Automating pK Prediction and the Preparation of Biomolecular Structures for Atomistic Molecular Modeling and Simulations,” Nucleic Acids Research40 (2012): W537-W541.

[34] L. Martinez, R. Andrade, E. G. Birgin, and J. M. Martinez, “P ACKMOL: A Package for Building Initial Configurations for Molecular Dynamics Simulations,” Journal of Computational Chemistry30 (2009): 2157-2164.

[35] W. L. Jorgensen, J. Chandrasekhar, J. D. Madura, R. W. Impey, and M. L. Klein, “Comparison of Simple Potential Functions for Simulating Liquid Water,” Journal of Chemical Physics79 (1983): 926-935.

[36] D. Van Der Spoel, E. Lindahl, B. Hess, G. Groenhof, A. E. Mark, and H. J. Berendsen, “GROMACS: Fast, Flexible, and Free,” Journal of Computational Chemistry26 (2005): 1701-1718.

[37] W. L. DeLano, “The PyMOL Molecular Graphics System,” CCP4 Newsletter on Protein Crystallography40 (2002): 82.

[38] E. Midavaine, J. Cote, and P. Sarret, “The Multifaceted Roles of the Chemokines CCL2 and CXCL12 in Osteophilic Metastatic Cancers,” Cancer and Metastasis Reviews40 (2021): 427-445.

[39] a) P. Buijs, S. van Nieuwkoop, V. Vaes, R. Fouchier, C. van Eijck, and B. van den Hoogen, “Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma,” Viruses7 (2015): 2980-2998. b) A. Ito, S. Itakura, Y. Hasegawa, et al., “Usefulness of Direct Intratumoral Administration of Doxorubicin Hydrochloride With an Electro-Osmosis–Assisted Pump,” Frontiers in Drug Delivery3 (2023): 1150894.

[40] A. A. Tokmakov, A. Kurotani, and K. I. Sato, “Protein pI and Intracellular Localization,” Frontiers in Molecular Biosciences8 (2021): 775736.

[41] D. G. Gamage, A. Gunaratne, G. R. Periyannan, and T. G. Russell, “Applicability of Instability Index for In Vitro Protein Stability Prediction,” Protein & Peptide Letters26 (2019): 339-347.

[42] A. Ikai, “Thermostability and Aliphatic Index of Globular Proteins,” Journal of Biochemistry88 (1980): 1895.

[43] W. Wang, Z. Zhong, Z. Huang, et al., “Two Different Protein Corona Formation Modes on Soluplus^® Nanomicelles,” Colloids and Surfaces. B, Biointerfaces 218 (2022): 112744.

[44] T. C. Terwilliger, D. Liebschner, T. I. Croll, et al., “AlphaFold Predictions Are Valuable Hypotheses and Accelerate but Do Not Replace Experimental Structure Determination,” Nature Methods21 (2024): 110-116.

[45] J. E. Park, N. K. Soung, Y. Johmura, et al., “Polo-box Domain: A Versatile Mediator of Polo-Like Kinase Function,” Cellular and Molecular Life Sciences67 (2010): 1957-1970.

[46] C. M. Deber, B. Brodsky, and A. Rath, “Proline Residues in Proteins,” Encyclopedia of Life Sciences (John Wiley & Sons Ltd., 2010).

[47] B. Maroto, M. B. Ye, K. von Lohneysen, A. Schnelzer, and U. G. Knaus, “P21-Activated Kinase is Required for Mitotic Progression and Regulates Plk1,” Oncogene27 (2008): 4900-4908.

[48] S. Schmucker and I. Sumara, “Molecular Dynamics of PLK1 During Mitosis,” Molecular & Cellular Oncology1 (2014): e954507.

[49] C. Lindon and J. Pines, “Ordered Proteolysis in Anaphase Inactivates Plk1 to Contribute to Proper Mitotic Exit in human Cells,” Journal of Cell Biology164 (2004): 233-241.

[50] S. J. Park, “Protein–Nanoparticle Interaction: Corona Formation and Conformational Changes in Proteins on Nanoparticles,” International Journal of Nanomedicine15 (2020): 5783-5802.

[51] Y. C. Shin, S. J. Song, Y. B. Lee, et al., “Application of Black Phosphorus Nanodots to Live Cell Imaging,” Biomaterials Research22 (2018): 31.

[52] Q. Hao, J. V. Vadgama, and P. Wang, “CCL2/CCR2 signaling in Cancer Pathogenesis,” Cell Communication and Signaling18 (2020): 82.

[53] R. Mezzapelle, M. Leo, F. Caprioglio, et al., “CXCR4/CXCL12 Activities in the Tumor Microenvironment and Implications for Tumor Immunotherapy,” Cancers (Basel)14 (2022): 2314.

[54] E. J. Sanchez-Barcelo and M. D. Mediavilla, “Recent Patents on Light Based Therapies: Photodynamic Therapy, Photothermal Therapy and Photoimmunotherapy,” Endocrine Metabolic & Immune Disorders8 (2014): 1-8.

[55] W. Li, J. Wu, L. Wu, et al., “Black Phosphorous Nanosheet: A Novel Immune-Potentiating Nanoadjuvant for Near-Infrared-Improved Immunotherapy,” Biomaterials273 (2021): 120788.

[56] Y. Miao, X. Wang, J. Sun, and Z. Yan, “Recent Advances in the Biomedical Applications of Black Phosphorus Quantum Dots,” Nanoscale Advances3 (2021): 1532-1550.

[57] C. Deng, L. Ren, L. Yang, et al., “Nonmonotonic Relationship Between the Degradation of Black Phosphorus and Its Bioactivity in Suppressing the Centrosome Polo-Like Kinase 1,” Environmental Science: Nano11 (2024): 278-293.

[58] V. Gorshkov, J. A. Bubis, E. M. Solovyeva, M. V. Gorshkov, and F. Kjeldsen, “Protein Corona Formed on Silver Nanoparticles in Blood Plasma is Highly Selective and Resistant to Physicochemical Changes of the Solution,” Environmental Science: Nano6 (2019): 1089-1098.

RIGHTS & PERMISSIONS

2025 The Author(s). Exploration published by Henan University and John Wiley & Sons Australia, Ltd.